Novo Nordisk
Выбор редакции
31 января, 01:27

Novo Nordisk Inks Diabetes Deal with University of Oxford

Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.

30 января, 13:29

Brexit Makes Scientists 20% Cheaper - Novo Nordisk Invests In Oxford Surprise

Why despite? We expect a fallen exchange rate to lead to more foreigners buying the now cheaper exports, to more foreigners investing in the now cheaper domestic assets. That's just what a fallen exchange rate does. So, the exchange rate falls, foreigners invest more, why is anyone surprised?

28 января, 01:37

Earnings Growth Returns, Will it Continue?

Earnings Growth Returns, Will it Continue?

Выбор редакции
18 января, 22:52

Why Company Success Relies On Integrated Thinking

Susanne leads Novo Nordisk’s efforts to be a sustainable business, charged with management of corporate sustainability-driven programs, the integrated Annual Report, stakeholder engagements and communication on the value of the company’s Triple Bottom Line (TBL) business principle. She is member of the International Integrated Reporting Council, member of the Board [...]

13 января, 22:20

Cory Booker Chooses Wall Street Over Main Street

Oh, Senator Cory Booker. I was so looking forward to 2020, in hopes that you would run for president. But now I fear that your 2020 campaign is doomed before it even starts. You are a talented and thoughtful senator. Your leadership on the issue of criminal justice reform made you a rock star in my world. But now you’ve revealed yourself to be just another Wall Street Democrat, out-of-touch with the concerns of Main Street America, just like your party’s doomed 2016 nominee, Hillary “I’m Not The Bad Man Who Says Bad Things” Clinton. This week, the Senate got on the fast track to its first agenda item in erasing any evidence there was ever a black president - the repeal of Obamacare. Democrats offered amendment after amendment to try and save any sliver of it they could. One by one, those amendments all failed. But one amendment would have passed. Senators Bernie “Maybe Next Time You’ll Pay Attention To Huge Rallies” Sanders and Amy “The Non-Franken Minnesotan” Klobuchar put forth an amendment to allow the importation of prescription drugs from Canada, in order to greatly reduce medication costs for Americans. Twelve Republicans voted for it, guaranteeing its passage if Democrats supported it. Senate Amendment 178: The Chairman of the Committee on the Budget of the Senate may revise the allocations of a committee or committees, aggregates, and other appropriate levels in this resolution for one or more bills, joint resolutions, amendments, amendments between the Houses, motions, or conference reports relating to lowering prescription drug prices, including through the importation of safe and affordable prescription drugs from Canada by American pharmacists, wholesalers, and individuals with a valid prescription from a provider licensed to practice in the United States, by the amounts provided in such legislation for those purposes, provided that such legislation would not increase the deficit over either the period of the total of fiscal years 2017 through 2021 or the period of the total of fiscal years 2017 through 2026. But some in the Democratic Party learned nothing from their electoral drubbing* and put the concerns of average Americans below the concerns of corporate campaign contributors. Given that choice, Senator Booker, you chose Wall Street over Main Street. You joined with Democratic senators Bennet (D-CO), Cantwell (D-WA), Carper (D-DE), Casey (D-PA), Coons (D-DE), Donnelly (D-IN), Heinrich (D-NM), Heitkamp (D-ND), Menendez (D-NJ), Murray (D-WA), Tester (D-MT), and Warner (D-VA) in ensuring Americans continue to pay the highest price for prescriptions in the world. Also, Senator Feinstein (D-CA) couldn’t be bothered to vote at all. You and some of the other Big Pharma Democrats are trying to sell us the excuse that you’re worried about the safety of imported drugs. We’re not stupid. We know that people have been illegally importing prescription drugs from Canada for years now; we saw Senator Bernie “Who’s The Unelectable One Now?” Sanders take busloads of seniors over the northern border to get cheap prescriptions filled and it didn’t seem to kill them off. We’ve got friends in Canada who use those drugs and their country hasn’t had any tainted prescription scandals. We know it is no coincidence that both New Jersey Democratic senators** voted against this amendment and there are 249 pharmaceutical companies headquartered in New Jersey. We know it is no coincidence that Merck & Co, Johnson & Johnson, Novo Nordisk, Novartis, and other health care industries have lined your pockets to the tune of over $945,474. We know it is no coincidence that your “worried about safety” excuse is the exact talking point promulgated by big pharma - literally PhRMA, the Pharmaceutical Research and Manufacturers Association: “The importation of unapproved and potentially counterfeit medicines into the United States jeopardizes our secure medicine system and presents a serious risk to public health,” a PhRMA spokesperson told HuffPost in a statement. “Guaranteeing patient safety is crucial, and we must have policies that ensure patients safely have access to the medicines they need.” The parents of a desperately ill child or the seniors whose lives depend on prescription medication aren’t worried that the pills they need are unsafe if they can’t afford to buy them in the first place. And Senator Booker, you knew full well that amendment only began the process of importing Canadian drugs, allowing Congress to further pass laws designed to ensure their safety. It’s not as if your YEA vote would have put Canadian pills in pharmacies tomorrow. Cory Booker, you have betrayed us. If you’re the Democrats’ hope for 2020, we all better prepare for eight years of a Trump Administration. ――   * And don’t you start in on the “3 million more votes” or “James Comey” or “Russian hacking” excuses. Hillary Clinton was running against an incompetent profane idiot narcissist on the heels of her party’s popular two-term incumbent who left her years of job growth, a surging stock market, increased health insurance coverage, reduced foreign occupations, and a dead Osama bin Laden to run on; she should have won by a landslide. Two-time Obama voters in the Rust Belt voted for Trump because they believed Hillary and the Democrats were oblivious to Main Street problems. Cory Booker and the Democratic Big Pharma caucus just proved them right. ** You’re not off the hook, either, Democratic Senators Murray ($2,732,660) and Cantwell ($1,096,243) from Washington (120 companies), Democratic Senators Carper ($1,136,706) and Coons ($620,668) from Delaware (15 companies, including Astra-Zeneca), and Democratic Senator Casey ($2,187,181) from Pennsylvania (211 companies, including GlaxoSmithKline and Johnson & Johnson). Y’all just aren’t running for president in 2020. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

13 января, 10:32

Фондовые индексы Европы снизились в четверг, но британский FTSE снова вырос

Европейские фондовые индексы завершили в минусе торги в четверг вслед за котировками акций автомобилестроительных и фармацевтических компаний, однако британский индикатор вновь увеличился и обновил рекорд.

12 января, 13:17

Европейские фондовые индексы снижаются в четверг, дешевеют акции ритейлеров

Европейские фондовые индексы снижаются в четверг вслед за котировками акций фармацевтических компаний.

Выбор редакции
12 января, 12:05

Novo Nordisk down 4.7% following news of lawsuit

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

11 января, 16:27

Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.

05 января, 16:06

Lilly Jardiance Family Diabetes Drugs' Label to be Updated

Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.

04 января, 20:20

Stock Research Reports for Comcast, Amgen & General Mills

Stock Research Reports for Comcast, Amgen & General Mills

04 января, 00:20

VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).

03 января, 09:59

Robust Design Compliance as a strong competitive advantage

Co-written by Anna Lykke Lundholm-Andersen Compliance with various standards in product development often amounts to intense requirements within both R&D and production. Implementing an optimized design method such as the one advanced by Danish engineering consultancy company, Valcon Design, can significantly impact these challenges. Applying the Pareto 80/20 optimization rule to compliance, stating that 80% of one's results stems from 20% of one's effort, allows Robust Design to focus and increase the efficiency of procedures and to provide a competitive advantage. The trick with Robust Design is to eliminate the costly iterations and thus make designs right the first time. Robust Design relies on the philosophy that optimization in design is the next evolutionary step within engineering. The new design (coined Six Theta® Design by Valcon Design) thus represents a major opportunity for industrial development companies to shorten the ramp-up time for R&D processes and create a more robust end-result by simplifying the designs, cutting off superfluous interfaces making the designs more tolerant towards over-constraints which usually force tighter tolerances that are expensive to achieve. According to Niels-Aage Hansen, Chief Engineer of Novo Nordisk, the definition of Robust Design is: "A design that is less sensitive to variation and that will therefore sustainably meet requirements. Working with Robust Design means optimizing the design by systematic assessment and calculations as opposed to the use of trial and error. The robustness KPIs are leading indicators for quality of the mechanical design." The industry has perfected standardized products via Six Sigma®. However, Robust Design represents a blind spot in the industry and by making initial rough calculations on designs one can reach a supreme level of predictability. This saves precious time on detailing the designing, testing and prototyping necessary to reach Sig Sigma® compliance. Thus, it is a far more efficient process for allocating the same resources to innovation and meeting the high demands of punctuality when releasing new products. During the one and a half year required for implementation, Novo Nordisk was shown to be the type of organization ready for the necessary change in mindset that Valcon Design wished to implement. Valcon Design wanted a change of culture in design methods and as the design changes were implemented throughout the organization from R&D to QA, these methods succeeded. The new design paradigm meant that engineers had to adapt to making rough calculations on designs before settling on one in particular. They also had to identify and eliminate 'design-waste', and production had to adjust to the new design. "To support and decide that Robust Design should be mandatory in Novo Nordisk Device R&D required an intense dialogue and training of our highly skilled engineers and production employees. The evident benefits of the Robust Design process carry a huge benefit for our manufacturing economy and improved patient experience long term." - Kenneth Strømdahl, senior vice president of Device R&D, Novo Nordisk. When analyzing non-compliant products, Valcon Design's engineers usually find approximately fifteen weaknesses per component in any given design. By being proactive about implementing the new design, companies can focus their resources on generating new products that put them in a superior competitive position instead of wrestling with complications from high tolerance demanding designs that have already exceeded budgets. With globalization comes an increased demand for ambidexterity and agility, industry is forced to seek out new paths in order to uphold a competitive position in an environment that keeps pressuring prices down. One is to lower the costs by moving production to low-cost countries whilst meeting the high compliance demands in production. Another is to simply be smarter about our designs, Special thanks to Anna Lykke Lundholm-Andersen for researching and co-writing this article -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.